Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Express Scripts
McKesson
Mallinckrodt
Merck

Last Updated: October 6, 2022

Details for Patent: 6,743,413


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,743,413
Title: Suspension aerosol formulations
Abstract:Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
Inventor(s): Schultz; Robert K. (Shoreview, MN), Schultz; David W. (Pine Springs, MN), Oliver; Martin J. (Loughborough, GB), Moris; Robert A. (Lino Lakes, MN), Jinks; Philip A. (Mount Sorrel, GB)
Assignee: 3M Company (St. Paul, MN)
Application Number:08/455,280
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,743,413
Patent Claim Types:
see list of patent claims
Formulation; Delivery; Use;

Drugs Protected by US Patent 6,743,413

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,743,413

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 150296 See Plans and Pricing
Austria 204743 See Plans and Pricing
Austria 260641 See Plans and Pricing
Australia 1234297 See Plans and Pricing
Australia 3272893 See Plans and Pricing
Australia 675633 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Boehringer Ingelheim
McKinsey
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.